Mahony Susan 4

What Happened Susan Mahony, a director of Axsome Therapeutics (AXSM), had 1,429 restricted stock units (RSUs) convert into 1,429 common shares on June 8, 2026. Following the conversion, she sold a total of 600 shares in two open‑market transactions (300 on June 9 at $237.21 and 300 on June 10 at $246.18), generating $71,163 and $73,854 respectively, for a combined proceeds of $145,017. The filing also shows a derivative disposal entry tied to the RSU settlement (1,429 shares at $0), which reflects the RSU conversion/withholding mechanics.

Key Details

• Transaction dates and prices: 6/8/2026 — conversion of 1,429 RSUs to common stock; 6/9/2026 — sale of 300 shares @ $237.21 ($71,163); 6/10/2026 — sale of 300 shares @ $246.18 ($73,854).
• Total cash proceeds from open‑market sales: $145,017.
• RSU grant/vesting: 1,429 RSUs were granted on June 6, 2025 and vested on the one‑year anniversary (per footnote).
• Plan/footnotes: Sales were made pursuant to a pre‑approved 10b5‑1 plan (now completed); shares were sold to cover taxes related to the RSU settlement.
• Shares owned after the transactions: not specified in the provided Form 4 excerpt.
• Filing timing: Form 4 filed 2026‑06‑10 (covers transactions dated 6/8–6/10); no late filing flag indicated in the provided details.

Context

• These transactions reflect RSU settlement and routine tax‑related selling rather than a new open‑market purchase — such sales are common when equity awards vest.
• The 10b5‑1 plan indicates the sales were pre‑arranged and not ad hoc.
• For retail investors: purchases by insiders can be a stronger signal of conviction than routine tax sales; this filing documents a conversion/settlement and partial sale to cover tax obligations, not a directional bet on the stock.